This application represents unprecedented cooperation among excellent institutions, major sarcoma dedicated non-profit organizations, and the NCI intramural Program. This SPORE originates from SARC, a non-for-profit consortium that facilitates the conduct of research among national centers of excellence in sarcoma. The main goals of the SARC Sarcoma SPORE are the translation of biological and technological advances into improvements in prevention, diagnostics, predictors of outcome, and - particularly - advances in the treatment of sarcoma. The SARC Sarcoma SPORE is anchored by multiple researchers from SARC, Harvard, MD Anderson Cancer Center, and the NCI intramural program, but also includes key individual researchers from Stanford University, Columbia University and The University of Michigan. The researchers represent medical and pediatric oncology and the projects explore both soft tissue and bone sarcomas. Four major projects are proposed: 1) HDACi-based therapeutic strategies for the treatment of genetically complex STS;2) Identification of therapeutic windows for NFI-related malignant peripheral nerve sheath tumor;3) Investigation of G-protein coupled receptors as biomarkers of aggressive disease and novel therapeutic targets in Ewing sarcoma;and 4) Development of quantitative imaging biomarkers for assessing therapeutic response to sarcoma therapy using advanced approaches in PET and MRl. These projects are integrated and supported by 4 cores: 1) Administration, Evaluation and Planning;2) Tissue and Pathology;3) Clinical Trials;and 4) Biostatistics. The SPORE application outlines a Developmental Research Program that includes a plan for selection of new projects as well as 14 proposed developmental pilot projects. We also include a Career Developmental Program that outlines a mechanism for the identification and support of talented young investigators in translational or clinical sarcoma research. The projects, cores and programs are highly integrated and are poised to take maximum advantage of the SPORE mechanism to achieve translational goals. This SPORE joins state-of-the-art research projects with the multi-institution, collaborative strength of SARC and commitments from leading institutions to produce translational advances.

Public Health Relevance

Currently, there are limited programs that have the capability to provide the infrastructure for collaboration on translational research for sarcoma. Because sarcoma is a relatively uncommon disease, this SARC Sarcoma SPORE will provide the infrastructure for translational research to develop and test the feasibility of cancer relevant interventions in humans and/or determine the biological basis for observations made in individuals with sarcoma.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
5U54CA168512-03
Application #
8725487
Study Section
Special Emphasis Panel (ZCA1-RPRB-7 (M1))
Program Officer
Ujhazy, Peter
Project Start
2012-09-26
Project End
2017-08-31
Budget Start
2014-09-01
Budget End
2015-08-31
Support Year
3
Fiscal Year
2014
Total Cost
$2,162,001
Indirect Cost
$96,023
Name
Sarc
Department
Type
DUNS #
186146911
City
Ann Arbor
State
MI
Country
United States
Zip Code
48106
Choy, Edwin; Ballman, Karla; Chen, James et al. (2018) SARC018_SPORE02: Phase II Study of Mocetinostat Administered with Gemcitabine for Patients with Metastatic Leiomyosarcoma with Progression or Relapse following Prior Treatment with Gemcitabine-Containing Therapy. Sarcoma 2018:2068517
Yu, Peter Y; Lopez, Gonzalo; Braggio, Danielle et al. (2018) miR-133a function in the pathogenesis of dedifferentiated liposarcoma. Cancer Cell Int 18:89
Ignatius, Myron S; Hayes, Madeline N; Moore, Finola E et al. (2018) tp53 deficiency causes a wide tumor spectrum and increases embryonal rhabdomyosarcoma metastasis in zebrafish. Elife 7:
Hawkins, Allegra G; Basrur, Venkatesha; da Veiga Leprevost, Felipe et al. (2018) The Ewing Sarcoma Secretome and Its Response to Activation of Wnt/beta-catenin Signaling. Mol Cell Proteomics 17:901-912
Lopez, Gonzalo; Pollock, Raphael E (2017) Evaluating the Effect of HDAC8 Inhibition in Malignant Peripheral Nerve Sheath Tumors. Methods Mol Biol 1510:365-374
Tang, Fan; Choy, Edwin; Tu, Chongqi et al. (2017) Therapeutic applications of histone deacetylase inhibitors in sarcoma. Cancer Treat Rev 59:33-45
Chen, James L; David, Jason; Cook-Spaeth, Douglas et al. (2017) Autophagy Induction Results in Enhanced Anoikis Resistance in Models of Peritoneal Disease. Mol Cancer Res 15:26-34
Haak, Andrew J; Appleton, Kathryn M; Lisabeth, Erika M et al. (2017) Pharmacological Inhibition of Myocardin-related Transcription Factor Pathway Blocks Lung Metastases of RhoC-Overexpressing Melanoma. Mol Cancer Ther 16:193-204
Hayashi, Masanori; Zhu, Peixuan; McCarty, Gregory et al. (2017) Size-based detection of sarcoma circulating tumor cells and cell clusters. Oncotarget 8:78965-78977
Smith, Steven C; Gooding, William E; Elkins, Matthew et al. (2017) Solitary Fibrous Tumors of the Head and Neck: A Multi-Institutional Clinicopathologic Study. Am J Surg Pathol 41:1642-1656

Showing the most recent 10 out of 111 publications